Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial.
Saved in:
| Title: | Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial. |
|---|---|
| Authors: | Xiang H; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA. hong.xiang@fiveprime.com., Liu L; Shanghai Qiangshi Information Technology Co., Ltd, Shanghai, China., Gao Y; Shanghai Qiangshi Information Technology Co., Ltd, Shanghai, China., Ahene A; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Macal M; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA.; TRex Bio, Inc., South San Francisco, CA, USA., Hsu AW; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA.; Merck and Co., South San Francisco, CA, USA., Dreiling L; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA., Collins H; Five Prime Therapeutics, Inc., 111 Oyster Point Blvd, South San Francisco, CA, 94080, USA. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Nov; Vol. 86 (5), pp. 595-606. Date of Electronic Publication: 2020 Sep 23. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1432-0843 |
|---|---|
| DOI: | 10.1007/s00280-020-04139-4 |
